Press Releases

February 3, 2025 Lupin Receives Tentative Approval from U.S. FDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets

February 1, 2025 Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations

January 28, 2025 Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.06%

January 28, 2025 Lupin and Avas Launch NaMuscla® in Italy

January 24, 2025 Lupin Receives U.S. FDA Approval for Sacubitril and Valsartan Tablets

January 24, 2025 Lupin Receives Approval from U.S. FDA for Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension

January 13, 2025 Lupin Launches Minzoya TM (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) in the United States

January 9, 2025 Lupin Receives Tentative Approval from U.S. FDA for Ivacaftor Oral Granules

January 9, 2025 Lupin Receives Tentative Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel